Recon: AstraZeneca gets partial liability protection in EU vaccine deal; Novavax COVID vaccine enters Phase 3

• How Trump is undermining his own vaccine race (Politico)
• Trump signs US healthcare executive orders that may have little impact (Reuters) (WSJ)
• Trump promises drug discount cards as a $200 pre-election gift (NYTimes) (STAT) (Reuters) (Politico)
• Cuomo says New York to review any COVID-19 vaccine authorized by federal government (Reuters) (NPR)
• US vaccine program chief backs stricter rules for emergency use of COVID-19 shot (Reuters)
• Next ‘Warp Speed’ Vaccine Matches Merck Experimental Product (Bloomberg)
• J&J signs manufacturing deal with GRAM for potential COVID-19 vaccine (Reuters)
• US appeals court rejects novel opioid settlement framework (Reuters)
• FDA flags health risks from 'Benadryl Challenge' (Reuters) (FDA)

• AstraZeneca gets partial immunity in low-cost EU vaccine deal (Reuters)
• China's annual mgf. capacity of COVID-19 vaccines expected to hit 610M by end-2020 (Reuters)
• A Bet on Europe Is a Bet on Drugs, Against Tech (WSJ)
• French labs show how global supply bottlenecks thwart effort to ramp up testing (Reuters)
• Novavax Enters Final Stage of Coronavirus Vaccine Trials (NYTimes)
• Endo starts manufacturing Novavax's potential COVID-19 vaccine (Reuters)
• Mexico has signed commitment to buy COVID-19 vaccines through COVAX (Reuters)
• Brazil to join COVAX vaccine facility, as Chile, Israel, UAE also sign up (Reuters)
• Some northern hemisphere countries struggling to source more flu vaccines: WHO (Reuters)
• Gilead's rheumatoid arthritis med filgotinib, after cold shoulder from FDA, wins global-first nod in Japan (Fierce)

• Trouble at the FDA and CDC (In The Pipeline)
• Science academies sound alarm on political interference (Politico)
• 'We need science to be the place of trust': How politics undermined the vaccine race (Politico)
• As FDA buckles under the strain of a pandemic workload, Trump again accuses the agency of a political hit job (Endpoints)
• Drugmakers push forward on large-scale production of coronavirus vaccines (BioPharmaDive)
• HHS wants to test 30% of U.S. wastewater for the coronavirus as an ‘early warning system’ (CNBC)
• Member of health secretary's security detail tests positive for coronavirus (Politico)
• China says WHO gave blessing for coronavirus vaccine emergency use programme (Reuters)
• Matt Hancock denies conflict of interest in Patrick Vallance holding vaccine company shares (Evening Standard)
• Africa has held off the worst of the coronavirus. Researchers are working to figure out how. (NBC)
• UK study shows rapid test has diagnostic sensitivity over 99% (Reuters)
• U.S. records over seven million COVID-19 cases as Midwest outbreak surges (Reuters)
• The ventilators never came: How graft hampered Brazil's COVID-19 response (Reuters)
• Coronavirus (COVID-19) Update: Daily Roundup September 24, 2020 (FDA)

• EMA Explains Dos And Don’ts Of New Clinical Trials Portal (Pink Sheet)
• Play-by-play of Gilead's $21B Immunomedics buyout details a frenzied push leading up to ESMO (Endpoints)
• Accord Healthcare launches Herceptin biosimilar in the UK (PharmaTimes)
• FDA sets January decision date for Xalkori in ALK-positive lymphoma (PMLive)
• Flagship's Valo emerges with $100M and plans to transform R&D (Fierce)
• The window is wide open as four more biotechs join the go-go IPO class of 2020 (Endpoints)
• Silverback dishes out two promotions in C-suite; Legend CEO post changes hands again (Endpoints)
• Gene therapy company Taysha completes sprint from first funding to IPO (BioPharmaDive)
• J&J offers PhI/IIa data showing its single-dose vaccine can stir up sufficient immune response (Endpoints)
• Palladio bags $20 million Series B to topple a problematic kidney disease drug (Endpoints)
• ENHERTU® Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric Cancer (Press)
• Newly prequalified Active Pharmaceutical Ingredient (API) (WHO)

• Medtronic-Axonics sacral neuromod patent battle heats up (MedtechDive)
• AdvaMed Launches Effort To Fight Misleading Lawsuit Ads (MedtechInsight)
• Exact Sciences wows investors with preliminary multi-cancer liquid biopsy data (MedtechDive)
• Recommendations About the Use of Dental Amalgam in Certain High-Risk Populations: FDA Safety Communication (FDA)

• J&J's next-gen Darzalex sparks drug delivery royalties battle (Fierce)
• Blue Cross Insurers Reach Tentative Settlement in Antitrust Lawsuit (NYTimes)
• Opioid MDL Negotiating Class Struck Down By 6th Circ. (Law360)
• D.C. Circ. Ponders $600M Rebate Switch Against Mallinckrodt (Law360)
• Genentech, Inc. and JHL Biotech, Inc. File a Stipulation for Entry of a Proposed Consent Judgment and Permanent Injunction; Court Order in Response Asks Parties to Answer Questions (Big Molecule Watch)
• Justice Department Announces Results in Fight Against the Opioid Crisis Two Years after Launch of Operation S.O.S. (DOJ)